Gene · 4595
Papers3,741
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
861 to 880 of 3,741
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. | World J Gastroenterol | 2022 | 35633912 | PubTator, text mining | PubMed |
| Oxidative Damage in Sporadic Colorectal Cancer: Molecular Mapping of Base Excision Repair Glycosylases MUTYH and hOGG1 in Colorectal Cancer Patients. | Int J Mol Sci | 2022 | 35628513 | PubTator, text mining | PubMed |
| The Role of DNA Repair in Genomic Instability of Multiple Myeloma. | Int J Mol Sci | 2022 | 35628498 | PubTator, text mining | PubMed |
| Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. | Cancers (Basel) | 2022 | 35626089 | PubTator, text mining | PubMed |
| Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients. | Cancers (Basel) | 2022 | 35626031 | PubTator, text mining | PubMed |
| Expression Profile of mRNAs and miRNAs Related to the Oxidative-Stress Phenomenon in the Ishikawa Cell Line Treated Either Cisplatin or Salinomycin. | Biomedicines | 2022 | 35625926 | PubTator, text mining | PubMed |
| Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. | Cell Rep Med | 2022 | 35617957 | PubTator, text mining | PubMed |
| Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis. | Cancer | 2022 | 35617463 | PubTator, text mining | PubMed |
| Clinical genetic testing in four highly suspected pediatric restrictive cardiomyopathy cases. | BMC Cardiovasc Disord | 2022 | 35614389 | PubTator, text mining | PubMed |
| Mutational signatures are markers of drug sensitivity of cancer cells. | Nat Commun | 2022 | 35614096 | PubTator, text mining | PubMed |
| Incident Cancer Risk and Signatures Among Older MUTYH Carriers: Analysis of Population-Based and Genomic Cohorts. | Cancer Prev Res (Phila) | 2022 | 35609203 | PubTator, text mining | PubMed |
| Germline mutations in Chinese ovarian cancer with or without breast cancer. | Mol Genet Genomic Med | 2022 | 35608067 | PubTator, text mining | PubMed |
| Clinician-Reported Impact of Germline Multigene Panel Testing on Cancer Risk Management Recommendations. | JNCI Cancer Spectr | 2022 | 35603838 | PubTator, text mining | PubMed |
| Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants. | Sci Rep | 2022 | 35595798 | PubTator, text mining | PubMed |
| Distinct landscapes of deleterious variants in DNA damage repair system in ethnic human populations. | Life Sci Alliance | 2022 | 35595529 | PubTator, text mining | PubMed |
| Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. | JAMA Netw Open | 2022 | 35594047 | PubTator, text mining | PubMed |
| Computational investigations on target-site searching and recognition mechanisms by thymine DNA glycosylase during DNA repair process. | Acta Biochim Biophys Sin (Shanghai) | 2022 | 35593467 | PubTator, text mining | PubMed |
| Potential genetic biomarker of Saudi Arabian patients with colorectal cancer. | Eur Rev Med Pharmacol Sci | 2022 | 35587061 | PubTator, text mining | PubMed |
| Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. | Nat Commun | 2022 | 35585047 | PubTator, text mining | PubMed |
| Current guidelines in the surgical management of hereditary colorectal cancers. | World J Gastrointest Oncol | 2022 | 35582097 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4595/papers?page=44